Skip to content

Ultragenyx Pharmaceutical RARE Total Cost of Revenue

Discontinued — last reported Q2 '19

Total Cost of Revenue at other companies

Eli Lilly logo
Eli LillyLLY
$3.58B+60.8%
Amgen logo
AmgenAMGN
$2.74B-7.5%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$2.98M+104%
Moderna logo
ModernaMRNA
$955M+961%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$9.94M+277%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$14.48M-19.2%

Other financials

Income statement

See full
Revenue$136.0M-2.2%
Operating income-$169.0M-18.2%
Net income-$185.0M-22.5%
EPS (diluted)-$1.84-17.2%

Balance sheet

See full
Cash & equivalents$175.0M+37.8%
Total debt$36.0M-10.8%
Total equity-$236.0M-264%
Total assets$1.3B-1.2%

Cash flow

See full
Operating cash flow-$197.0M-18.7%
CapEx$1.0M0.0%
Free cash flow-$198.0M-18.6%

Valuation

See full
Market cap$2.83B-39.4%
P/S4.2×-3.7×

Profitability

See full
Gross margin97.2%
Operating margin-83.8%-3.0pp
Net margin-90.9%-2.1pp
FCF margin-75.1%+10.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×
Current ratio-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed August 2, 2019, on SEC EDGAR. View the filing →

Questions, answered.

What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.